A comparison of the therapeutic efficacy of Tenofovir Disoproxil Fumarate and Entecavir in patients with chronic Hepatitis-B | [Pakistan Journal of Medical Sciences • 2024]

Author(s):

1. Huan Wang: Department of Infectious, First People’s Hospital of Linping District, Hangzhou, Zhejiang Province 311100, P.R. China.

2. Liping Wu: Department of General Geriatrics, Linping District Integrated Traditional, Chinese and Western Medicine Hospital,369 Yingbing Road, Hangzhou, Zhejiang Province 311100,P.R. China

Abstract:

Objective: To compare the therapeutic eficacy of tenofovir disoproxil fumarate (TDF) and entecavir (ETV) in patients with chronic Hepatitis-B (CHB). Methods: This retrospective study included 110 patients with CHB who received treatment at The First People's Hospital of Linping District, Hangzhou from January 2021 to January 2023. Clinical data of the patients were reviewed and the patients were classified according to the treatment received: TDF group (n=53, patients received TDF treatment) and ETV group (n=57, patients received ETV treatment). Hepatitis-B virus deoxyribonucleic acid (HBV DNA) levels, liver function indicators, hepatitis-B e antigen (HBeAg) seroconversion rate, alanine transaminase (ALT) normalization rate, HBV DNA negative conversion rate, overall eficacy, and incidence of adverse reactions were compared. Results: The total eficacy of the treatment in the TDF group was 94.33%, significantly higher than that in the ETV group (78.95%; P<0.05). After the treatment, the HBV DNA levels in both groups decreased compared to pretreatment levels, and were significantly lower in the TDF group compared to the ETV group (P<0.05). Both groups showed significant post-treatment improvement in liver function that was markedly better in the TDF group compared to the ETV group (P<0.05). The HBeAg seroconversion rate, ALT normalization rate, and HBV DNA conversion rate in the TDF group were significantly higher compared to the ETV group (P<0.05). There was no diference in the incidence of adverse reactions between the two groups. Conclusions: Compared with ETV, TDF has comparable adverse reaction profile but has more significant clinical efects in patients with CHB, improving HBeAg seroconversion rate, ALT normalization rate, and HBV DNA negative conversion rate. TDF is associated with lower HBV DNA levels after treatment and better improvements in liver function of patients.

Page(s): 2390-2394

DOI: 10.12669/pjms.40.10.10307

Published: Journal: Pakistan Journal of Medical Sciences, Volume: 40, Issue: 10, Year: 2024

Keywords:

Tenofovir disoproxil fumarate , Entecavir ETV , Chronic HepatitisB , HepatitisB virus deoxyribonucleic acid , HBeAg seroconversion

References:

[1] Pak J Med Sci .2019 .. , 10(6) : 1364-1569.

[2] .2022 .workers of women beauty salons. Pak J Med Sci, 38(8) : 2156.

[3] . .. , 10 : 6166.

[4] .2022 .. , 04(3) : 642-652.

[5] . .Assembly Modulator GLS4 in Patients With Chronic HBV Infec-. , : .

[6] .2021 .. Clin Infect Dis, 10(2) : 175-182.

[7] .2018 .. , 10(51) : .

[8] .2023 .. Expert Rev Gastroenterol Hepatol, 17(6) : 623-633.

[9] .2023 .. doi: 10.1080/17474124, : .

[10] . .With Human Immunodeficiency Virus Type 1 Infection: Week 96. , : .

[11] . .Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD. , : .

[12] Trial Noninferiority .2021 .. Clin Infect Dis, 10(1) : 33-42.

[13] . .. cid/ciaa822, : .

[14] pregnancy (IMPAACT .2010 .A multicentre, open-label,. , : .

[15] .2021 .randomised, controlled, phase 3 trial. , 397(10281) : 1276.

[16] . .. , 6736(21) : 00314-7.

[17] Sriprayoon T,Mahidol C,Ungtrakul T,Chun-On P,Soonklang K,Pongpun W .2017 .Efficacy and safety of entecavir versus tenofovir treatment in chronic Hepatitis-B patients: A randomized controlled trial. Hepatol Res, 10(3) : E161-E168.

[18] Jeong S,Shin HP,Kim HI .2022 .Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis-B. , 10(2) : 94-103.

[19] Ma X,Liu S,Wang M,Wang Y,Du S,Xin Y .2020 .Tenofovir Alafenamide Fumarate, Tenofovir Disoproxil Fumarate and Entecavir: Which is the Most Effective Drug for Chronic Hepatitis-B? A Systematic Review and Meta-analysis. J Clin Transl Hepatol, 00164(3) : 335-344.

[20] Yang S,Ma X,Cai C,Wang H,Xiao F,Yu C .2021 .Tenofovir Disoproxil Fumarate Is Superior to Entecavir in Reducing Hepatitis-B Surface Antigen for Chronic Hepatitis-B in China: 2-Year Comprehensive Comparative Result of a Matched Comparative Study. Front Med (Lausanne), 10 : 637126.

[21] Kim HJ,Kim JH,Yeon JE,Seo YS,Jang JW,Cho YK .2022 .Double-Blind Randomized Controlled Phase III Clinical Trial to Evaluate the Antiviral Activity and Safety of DA-2802 (Tenofovir Disoproxil Orotate) and Viread (Tenofovir Disoproxil Fumarate) in Chronic Hepatitis-B Patients. J Korean Med Sci, 37(11) : .

[22] Liu Z,Jin Q,Zhang Y,Gong G,Wu G,Yao L .2021 .Randomised clinical trial: 48 weeks of treatment with Tenofovir amibufenamide versus Tenofovir disoproxil fumarate for patients with chronic Hepatitis-B. Aliment Pharmacol Ther, 10(9) : 1134-1149.

[23] Luo W,Xin H,Zhao P,Jiang S. .2021 .Effects of HBeAg Status on cellular immune function of patients with Hepatitis-B virus/Treponema Pallidum Co-infectio. Pak J Med Sci, 10(7) : 4253-1876.

[24] Pan CQ,Chang TT,Bae SH,Brunetto M,Seto WK,Coffin CS .2021 .Antiviral kinetics of Tenofovir alafenamide and Tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV. PLoS One, 10(5) : .

[25] Yin Z,Shen B .2022 .Comparative study of the effect of U100 laser and pneumatic ballistic combined with percutaneous transhepatic cholangioscopic lithotomy in the treatment of intra-and extrahepatic bile duct stones and its effect on liver function. Pak J Med Sci, 10(6) : 5903-1690.

[26] Hsu YC,Suri V,Nguyen MH,Huang YT,Chen CY,Chang IW .2021 .Inhibition of Viral Replication Reduces Transcriptionally Active Distinct Hepatitis-B Virus Integrations With Implications on Host Gene Dysregulation. Gastroenterology, 12(4) : 1160-1170.

[27] Bazinet M,Pântea V,Placinta G,Moscalu I,Cebotarescu V,Cojuhari L,Tenofovir Disoproxil .2020 .Pegylated Interferon Alfa2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy. Gastroenterology, 02(8) : 2180-2194.

[28] Murata K,Mizokami M. .2023 .Possible biological mechanisms of Entecavir versus Tenofovir disoproxil fumarate on reducing the risk of hepatocellular carcinoma. J Gastroenterol Hepatol, 10(5) : 683-691.

[29] Chang KC,Lee CY,Chang TS,Hung CH,Chen WM,Chen MY .2020 .Usefulness of quantitative Hepatitis-B surface antigen testing in Hepatitis-B community-based screening. J Formos Med Assoc, 08(2) : 847-853.

Citations

Downloads

Views